PlexusDx emphasizes precision-matched treatment planninginformed by both clinical evidence and individual biomarker contextrather than assuming all patients benefit equally from combination therapy
Compounded products do not have the same room temperature allowance as brand-name pens, so professional guidance is important here
5 As we continue to understand the full spectrum of GLP-1s impact, these findings underscore its potential as a powerful tool in both metabolic and inflammatory health
Although strict glycemic control has beneficial effects on microvascular complications (retinopathy, nephropathy or neuropathy), it does not seem to reduce the risk of cardiovascular disease, and it is associated with an increased risk of hypoglycemia in patients with DM2.3,6 Until recently, the antihyperglycemic drugs available have improved glycemic control, but without much benefits on cardiovascular and/or renal risk
Moreover, we detected increased expression of cleaved caspase 3 and decreased GSDME cleavage product (GSDME-N) in NSBSO-treated cells (Fig
The STEP trials demonstrated that semaglutide produces 1522% body weight reduction over 68 weeks in people with obesity, significantly outperforming diet and exercise alone
